MedPage Today

FDA Approves Zanidatamab Combination for HER2-Positive Gastroesophageal Cancer

(MedPage Today) -- The FDA approved zanidatamab (Ziihera) plus tislelizumab (Tevimbra) and chemotherapy as first-line treatment for unresectable/metastatic HER2-positive gastroesophageal cancer. The approval stipulates use in adults with unresectable...